PTPN11 and neoplasm: Fedele et al. found that G12C/SHP2 inhibition increased CD8+ T cell infiltration into the tumour microenvironment, and triple therapy with PD-1 inhibitors resulted in greater tumour regression in PDAC murine models [60].